Related Experiment Video
Updated: Sep 19, 2025
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies
Ahmet Yildirim1, Marcus W Moses2, Margo Gerke2
1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Abstract:
Non-clear cell renal cell carcinomas (nccRCC) comprise a heterogeneous group of rare malignancies, accounting for approximately 20% of all kidney cancers. Given the rarity of these diverse subsets of RCC, the treatment paradigm for nccRCC is often based on treatment strategies utilized in the management of clear cell renal cell carcinoma (ccRCC), which may not fully address the distinct molecular and genetic drivers unique to nccRCC tumors. However, recent advances in the molecular characterization of nccRCC have led to the identification of new therapeutic targets, resulting in the development of more targeted therapies for nccRCC treatment. Furthermore, the role of molecular characterization of renal tumors is emphasized in the 2022 World Health Organization reclassification of genitourinary tumors, given that delineation of renal tumor subtypes now also relies on genetic markers. In order to highlight this evolving treatment landscape, our review provides a comprehensive summary of recent progress related to the biology and management of nccRCC subtypes.
Insights
Non-clear cell renal cell carcinomas (nccRCC) are rare kidney cancers often treated with clear cell RCC strategies. Advances in molecular characterization are revealing unique targets for developing more effective, targeted nccRCC therapies.
Area of Science:
- Oncology
- Genitourinary Pathology
- Molecular Diagnostics
Background:
- Non-clear cell renal cell carcinomas (nccRCC) represent a rare and heterogeneous group of kidney cancers, comprising about 20% of all renal malignancies.
- Current treatment for nccRCC often relies on strategies developed for clear cell renal cell carcinoma (ccRCC), which may not be optimal due to distinct molecular drivers.
- The 2022 World Health Organization reclassification highlights the increasing importance of molecular and genetic markers in defining renal tumor subtypes.
Purpose of the Study:
- To provide a comprehensive overview of the latest advancements in the biology and management of non-clear cell renal cell carcinoma subtypes.
- To emphasize the evolving landscape of targeted therapies driven by molecular characterization of nccRCC.
- To inform clinicians and researchers about the significance of genetic markers in nccRCC diagnosis and treatment.
Main Methods:
- Literature review of recent studies on nccRCC biology and treatment.
- Analysis of molecular and genetic findings in various nccRCC subtypes.
- Synthesis of information regarding emerging targeted therapies for nccRCC.
Main Results:
- Recent molecular characterization of nccRCC has identified novel therapeutic targets.
- Development of targeted therapies tailored to the specific molecular drivers of nccRCC is advancing.
- The integration of genetic markers is crucial for accurate subtyping and personalized treatment of renal tumors.
Conclusions:
- Understanding the unique molecular profiles of nccRCC subtypes is essential for effective treatment.
- Targeted therapies based on molecular characterization offer promising new avenues for nccRCC management.
- The evolving classification and diagnostic approaches underscore the need for continued research in nccRCC.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...